Freshly isolated PBMCs from a R/R DLBCL patient were treated with increasing gemcitabine concentrations (and vehicle control) for 5h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.